349
Participants
Start Date
July 31, 2014
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2018
PRT-201
Placebo
Mount Sinai Medical Center, New York
VA Pittsburg Healthcare System, Pittsburgh
Lehigh Valley Health Network, Allentown
University of Maryland, Baltimore
University of Maryland Shore Medical Center at Easton, Easton
Wake Forest, Winston-Salem
University of North Carolina at Chapel Hill, Chapel Hill
Duke University, Durham
W.G. Hefner VA Medical Center, Salisbury
University of Alabama at Birmingham, Birmingham
University of Louisville, Louisville
Ohio State University, Columbus
University of Cincinnati Medical Center, Cincinnati
University of Cincinnati, Cincinnati
Lutheran Hospital Network of Indiana, Fort Wayne
University of Iowa Hospitals and Clinics, Iowa City
Rush Medical Center, Chicago
Renal Care Associates, Peoria
Tulane University, New Orleans
Louisiana State University Health Sciences Center, Shreveport
The University of Oklahoma College of Medicine, Tulsa
The Methodist Hospital, Houston
AKDHC Medical Research Services , LLC, Phoenix
AKDHC Medical Research Services, LLc, Tucson
Keck University Hospital at USC, Los Angeles
VA Medical Center Long Beach, Long Beach
Kaiser Permanente Medical Center, San Diego
California Institute of Renal Research, San Diego
Alliance Research Center, Laguna Hills
UCSF Division of Vascular & Endovascular Surgery, San Francisco
Lake Washington Vascular Center, Bellevue
Maine Medical Center, Portland
Beth Israel Deaconess Medical Center, Boston
Brigham and Women's Hospital, Boston
University of Massachusetts Medical Center, Worcester
Lead Sponsor
Proteon Therapeutics
INDUSTRY